Nexalin Technology, Inc. announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device, has been granted regulatory approval by the Sultanate of Oman?s Ministry of Health.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 USD | +5.77% | -20.31% | +171.74% |
1st Jan change | Capi. | |
---|---|---|
+171.74% | 8.18M | |
+4.98% | 213B | |
+7.44% | 184B | |
+28.22% | 153B | |
+33.19% | 113B | |
+0.76% | 63.66B | |
+16.51% | 53.53B | |
+1.45% | 49.11B | |
-4.53% | 38.73B | |
+2.74% | 36.26B |
- Stock Market
- Equities
- NXL Stock
- News Nexalin Technology, Inc.
- Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device